|
Jun 13
|
Syndax reports publication of revumenib data from BEAT AML trial
|
|
Jun 12
|
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
|
|
Jun 12
|
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
|
|
Apr 2
|
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
|
|
Feb 24
|
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
|
|
Feb 20
|
Here's Why We're Watching Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
|
|
Jul 29
|
FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks
|
|
Jul 29
|
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
|
|
Jul 25
|
Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet
|
|
Jul 25
|
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024
|
|
Jun 14
|
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
|
|
May 15
|
Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
|
|
May 12
|
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
|
|
May 9
|
Syndax Pharmaceuticals Inc (SNDX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
|
May 8
|
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
|
|
May 1
|
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
|
|
Apr 10
|
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
|
|
Apr 8
|
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
|
|
Mar 28
|
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
|